On 11 April 2024, Formycon AG and Bioeq AG announced the launch of Lucentis® (ranibizumab) biosimilar FYB201 in Canada and Switzerland. Health Canada granted marketing authorization under the tradename RanoptoTM, and Swissmedic has approved FYB201 under the tradename Ranivisio®.
FYB201 was developed by Bioeq AG subject to the joint venture between Formycon AG and Polpharma Biologics Group BV. In mid 2021, Bioeq entered an exclusive commercialisation agreement with Teva for FYB201 in Canada and Europe (among other regions).